MANAUSDTIf the price goes out of the bearish channel in this way, it can easily increase to the blue range of $ 1,2294 !!!
Of course, the risk of decreasing from the bottom to the yellow range ($ 0.55578) should be considered !!!
Buysignal
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well.
Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year.
Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
$RYTM Next Target PTs 5.50-6.50 and higherRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
KDAUSDTin my opinion this coin is on support zone
entries is clear but the stop for the second position will be updated after the price break the trend line
TWTUSDTTrue, the whole market is negative, but it has managed to maintain its upward channel
Most importantly, we did not miss the limits!
It seems to be able to show a positive reaction on the price range of $ 0.5193 and have an upward trend up to the specified range.
GBPUSD buy opportunitywe have 2 way to buy gbpusd after it down to support level or after breakout 1.2340
our buy target
1- 2420
2- 2520
Btc trade take booked profiti have taken a trade today based on indicator and a bit of chart analysis
CADCHF Long Trade OpportunityA 'buy' opportunity has just presented itself on the loonie-swissy trading chart. This is occasioned by the bullish harami candlestick pattern which closes just above the 0.74593 horizontal support level, which signals a fakeout and suggests an upward price movement.
You can still enter this trade by setting your stop slightly below the level mentioned earlier and placing your target anywhere between your entry price and the 0.78000 psychological level (ensuring a reward-to-risk ratio of at least 3.00).
Happy trading!
Buy and Sell possibilities for Chainlink Simple chart to guide buy and sell opportunities. This is just a projection. Do your own research.
OIL 1hr Buy SignalStochastic RSI 20% bullish crossing is a dependable buy signal (or sell signal).
The stop should go below the current recent higher low. Remember to use 1% risk
maximum so calculate your position size correctly.
Can we Fill the Clean Range? (GBPUSD)Hi Traders,
GBPUSD has broken a 4-hour resistance level, The current h4 candle has wicked down to come all the way up and break structure, That is a sign of a lot of money being poured into the buys, I do expect the continuation and I would love to see price retest the broken resistance and then go for the highs of 1.2825.
We will, as always, need to see the price close above before even considering the buys, To back up my analysis we also have an inverse head and shoulders.
Happy Trading.
Renaldo Philander
$AERC entry PTs 16-17.70 Next Target PT 28 and higher Long term AeroClean Technologies, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. The company offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. It provides Purgo, an air sanitization product for indoor spaces; and Purgo Lift that provides air purification solution for elevators and other wall-mount applications. The company was formerly known as AeroClean Technologies, LLC. AeroClean Technologies, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.
$AUVI Next Target PT 4.50 and higher Long term PT 35 and higherApplied UV, Inc., through its subsidiaries, develops, acquires, and commercializes technology that addresses air purification and infection control in the healthcare, hospitality, commercial, municipal, and residential markets in the United States, Canada, and Europe. It operates through Disinfection and Hospitality segments. The company offers science-based solutions and products in air purification under the Airocide brand; and disinfection of hard surfaces under the Lumicide brand. It also manufactures and supplies fine decorative framed mirrors, framed arts, and bathroom vanities. The company was incorporated in 2019 and is headquartered in Mount Vernon, New York.
$CMRA entry PTs 2.25-3 Long term PT 30 and higherComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
$QNGY entry PTs .40-.45 Long term PT 40 and higher Quanergy Systems, Inc. develops and markets light detection and ranging (LiDAR) solutions for automotive and IoT applications. The company offers M1 LiDAR sensor for mid-long range industrial measurement applications; M1 Edge 2D LiDAR sensor that enables reliable collision avoidance and smart navigation; M8 LiDAR sensor, which provides 3D perception using multiple eye-safe laser beams and time-of-flight measurement technology; MQ-8 LiDAR sensor for flow management applications; M8-Prime 3D LiDAR sensor that provides industry-leading pinpoint accuracy and captures for industrial and mapping applications; S3 solid state LiDAR sensor; QORTEX DTC, a 3D computer perception software; and QORTEX people counter enables the development of accurate and innovative people counting and queue management applications. Its products are used in various applications, such as mapping, security, smart city and smart spaces, industrial automation, and transportation applications. The company was founded in 2012 and is headquartered in Sunnyvale, California.
GBPCHF longJumping in on a buy, this is after analysis of previous market patters, which suggest the price should now go up.
Agilent looking for technology rallyMy models say the Fed cannot raise rates beyond 0.5 points tomorrow or they cannot be trusted in the future. We should see a quick rally to end this week and perhaps begin next week, before the reality of $6+ fuel prices set in again and we continue the bear market.
Based on historical movement, the trough could occur anywhere in the larger red box. The final targets are in the green boxes. The pending top should occur within the larger green box as has been the historical case. Half of all movement has ended in the smaller green box. In this instance, the signal indicated BUY on June 10, 2022 with a closing price of 121.62.
If this instance is successful, that means the stock should rise to at least 122.53 which is the bottom of the larger green box. Three-quarters of all successful signals have the stock rise 2.205% from the signal closing price. This percentage is the bottom of the smaller green box. Half of all successful signals have the stock rise 3.812% which is the end point of the black dotted arrow. One-quarter of all successful signals have the stock rise 6.56% from the signal closing price which is the top of the smaller green box. The maximum rise on record would see a move to the top of the larger green box. These are the same concepts for the levels in the red boxes as well.
The ends/vertical sides of the boxes are determined in a similar fashion. The peak of the rise can occur as soon as the next trading bar after signal close, while the max rise occurs within the limit of study at 50 trading bars after the signal. A 0.4% rise must occur over the next 50 trading bars in order to be considered a success. Three-quarters of successful movement occur after at least 18 trading bars; half occur within 28 trading bars, and one-quarter require at least 38 trading bars.
The black dotted arrow represents median historical movement. Medians are a good metric, but they are just one of many I use when forecasting future movement.
As always, the stock could decline the very next bar after the signal without looking back (therefore the red boxes would not come into play) or the stock may never decline (and the green boxes may never come into play).
$UCO ready to go higher after retesting broken resistance?Notes:
* Strong up trend due to macro situations
* Printed a Pocket Pivot as it bounced off of broken resistance
* Looks good on multiple time frames
Technicals:
Sector: Exchange Traded Fund
Relative Strength vs. Sector: 3.02
Relative Strength vs. SP500: 4.05
U/D Ratio: 1.62
Base Depth: 56.08%
Distance from breakout buy point: 4.42%
Volume 37.69% above its 15 day avg.
Trade Idea:
* You can enter now as the price just bounced off of the broken resistance with higher than average volume
* If you're looking for a better entry you look to buy around the $52.20 area
* Manage risk accordingly
AVAXUSDTVery clean template being completed.
Should the vision go according to the scenario? If we go according to the scenario, we can have an interesting deal.
Must see ...
$ETH Demand Zone, volume spike sellers are about to get squeezedIMO ETH is now setting up to be a potentially highly lucrative play, human emotion specially fear is an angle we will play off of to make money. Basic fib levels and or or movement indicate a bounce exactly at this level, worth that being said I expect to see some bouncing in price within a range before an actual breakout. PoS is inevitable and will address many issues ETH faces, L2 Dapps, data sharding, this is a once in a lifetime opportunity.
Bitcoin Cash BCH short Entry Range, Take Profit and Stop LossBCH/USDT
Entry Range: $130 - 145
Price Target 1: $119
Price Target 2: $105
Price Target 3: $95
Stop Loss: $167
Long TradeHi my friend
This analysis is just a possibility, and you are responsible for your own trades.
Thanks.
